A groundbreaking study led by researchers at the University of Michigan’s Institute for Healthcare Policy and Innovation (IHPI) reveals that Medicaid itself may be a crucial catalyst enabling employment, rather than a hindrance. Contrary to the rationale behind work requirements, the research demonstrates that possessing Medicaid coverage is strongly associated with increased employment, especially among individuals facing substantial health burdens. The study integrates sophisticated measures of health status with detailed employment outcomes, providing novel insights into how improved health might translate into better workforce participation.

Medicaid enrollees with significant health challenges showed a remarkable improvement in employment rates when their health status improved. The study tracked over 4,000 enrollees of Michigan’s Healthy Michigan Plan (HMP) from 2016 to 2018, analyzing longitudinal health surveys and employment records. Findings showed that those beginning with significant health impairments who reported health improvements had their employment nearly double—from 26% to 47%. This dramatic increase contrasts with the lower employment rates among those whose health remained static or deteriorated.

The relationship between health improvements and employment gains was not isolated to those with severe health limitations. Enrollees with moderate health burdens who experienced better health also increased workforce participation significantly—rising from 48% employment at baseline to 67% by the study’s end. Even among participants with minimal initial health burdens, employment rates improved from 59% to 71%, indicating that health status and employment are intertwined across the spectrum of health conditions.

Central to understanding the policy implications of these findings is the definition and operationalization of “health burden.” The IHPI team crafted a multidimensional health burden metric incorporating both physical and mental health dimensions. This included quantifying the number of days within the previous month individuals experienced poor health or activity limitations. This nuanced approach allowed the study to capture not only chronic illness diagnoses but also functional health status, which is intimately linked to individuals’ ability to work.

Such data-driven evidence challenges the premise underlying the forthcoming work requirements. Requiring Medicaid recipients to prove employment may inadvertently penalize those whose health challenges would benefit from Medicaid coverage, which in turn supports their eventual workforce integration. The study’s lead author, Dr. Minal Patel, underscores that Medicaid expansion “doesn’t discourage work—it helps make it possible.” In essence, the health benefits provided through Medicaid can serve as an enabling mechanism for employment, especially for the most vulnerable populations.

Policy discussions often frame Medicaid as a welfare program that disincentivizes employment, but this research flips that narrative by showing causality in the opposite direction. Health coverage and resultant health improvements precede and contribute to employment gains, suggesting that restricting access through work requirements could reduce workers’ potential and deepen health inequities. This nuanced understanding is critical as states prepare to implement these mandates starting in 2027.

The study’s context is grounded in Michigan’s Healthy Michigan Plan, a state-specific Medicaid expansion program that enrolls approximately 716,000 low-income residents. Eligibility in this program is defined primarily by income, with an upper threshold at 133% of the federal poverty level, translating to around $16,500 annually for a single individual during the study period. This income level aligns with roughly $8 per hour for a full-time job, highlighting that enrollees represent individuals on the cusp of economic marginality.

Interestingly, at baseline in 2016, only 48% of enrollees reported being employed, a figure significantly lower among those with substantial health issues. The employment trajectory tracked in subsequent years shows that health improvements can catalyze meaningful labor market outcomes, potentially informing broader socioeconomic interventions aimed at reducing poverty and enhancing community wellbeing.

This analysis, conducted prior to the brief implementation and subsequent federal court suspension of Michigan’s Medicaid work requirements in 2020, offers a prescient look at likely unintended consequences if similar policies are pursued more broadly. The Congressional Budget Office projects that nearly 5 million individuals could lose Medicaid coverage between 2027 and 2034 due to work requirement policies, even when eligible. Such losses risk reversing critical health and employment gains documented in this study.

The rigor of this research stems from a robust methodological approach. Using longitudinal survey data, the study evaluates health trajectories alongside employment status changes, enabling a causal interpretation that many cross-sectional studies cannot provide. The interdisciplinary team behind this work includes experts in public health, medicine, policy evaluation, and healthcare innovation, bolstering the study’s credibility and policy relevance.

These findings compel policymakers and stakeholders to reconsider the relationship between health coverage and employment incentives within Medicaid. Rather than imposing barriers that may exacerbate health-related work limitations, strategies that enhance access and support health improvements might offer more sustainable and equitable pathways toward economic stability for low-income populations.

In conclusion, the University of Michigan’s recent research provides compelling evidence that Medicaid coverage serves as a foundational resource enabling beneficial health changes that underpin improved employment outcomes. As states navigate the complex implementation of federally mandated work requirements in Medicaid, these results advocate for policies that recognize health improvement as a vital precursor to workforce engagement—not an obstacle to it.

Subject of Research: People

Article Title: Employment and Health Burden Changes Among Medicaid Expansion Enrollees

News Publication Date: 31-Oct-2025

Web References:
https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2025.4639

References:
Patel M., Goold S., et al. Employment and Health Burden Changes Among Medicaid Expansion Enrollees. JAMA Health Forum. 2025; DOI: 10.1001/jamahealthforum.2025.4639.

Keywords:
Health care policy, Health care, Health disparity, Health equity, Insurance, Health insurance, Poverty

Central to this discovery are neurons located within the ventromedial nucleus of the hypothalamus (VMH), a brain region long recognized for regulating hunger, fear, thermoregulation, and reproductive behaviors. Specifically, the study zeroes in on neurons expressing the cholecystokinin B receptor (Cckbr). These VMH^Cckbr neurons demonstrate a pivotal role not in crisis management but in maintaining baseline glucose levels, especially during the nocturnal fasting phase between the last meal and waking hours—a time frame critical for preventing hypoglycemia overnight.

To elucidate the function of VMH^Cckbr neurons, the research team employed genetically engineered mouse models in which these neurons could be selectively inactivated. Monitoring glucose dynamics in these models revealed a compelling finding: inactivation disrupted normal glucose maintenance during fasting. This indicates that VMH^Cckbr neurons send signals which subsequently prompt peripheral tissues to sustain blood glucose levels. Intriguingly, the mechanism by which these neurons operate involves stimulating lipolysis—the metabolic breakdown of fats—thereby releasing glycerol, a gluconeogenic substrate essential for glucose production. This biochemical pathway highlights a sophisticated brain-to-body communication network that supports metabolic equilibrium outside emergency scenarios.

Activating the VMH^Cckbr neurons caused an elevation in circulating glycerol in mice, further corroborating their role in modulating lipolysis. This glut of glycerol feeds the liver’s gluconeogenesis process, effectively ensuring a steady supply of glucose to vital organs during fasting. Such continuous microscopic modulation stands in contrast to the prevailing belief of a binary on/off regulatory system, which postulated that neuronal influence on glucose is predominantly reactive and emergency-driven rather than proactive and preventative.

These insights hold profound implications for understanding metabolic disorders like prediabetes and type 2 diabetes. Patients with prediabetes experience unexplained increases in nocturnal lipolysis, a phenomenon that may stem from hyperactivity of VMH^Cckbr neurons. Overactivation of this circuit could lead to excessive glucose production, precipitating elevated blood sugar levels that characterize diabetes onset. By pinpointing this neural pathway, researchers have opened avenues for targeted interventions that could recalibrate excessive gluconeogenic signaling, potentially mitigating early metabolic dysregulation.

In addition, the study underscores the multifaceted nature of hypothalamic control over metabolism. While VMH^Cckbr neurons regulate lipolysis, not all neuron types in the ventromedial nucleus have been linked to this metabolic branch, indicating the presence of distinct populations orchestrating varying aspects of glucose regulation. This multiplicity allows the brain to fine-tune metabolic responses based on context, such as feeding, fasting, and stress, thus maintaining homeostasis through a balanced integration of neural signals.

The researchers emphasize that glucose regulation is not a simplistic, all-or-nothing neural event but rather a harmonious interplay of diverse neuron clusters whose activity fluctuates with physiological needs. Under stress or emergency, this network intensifies its efforts, but during everyday metabolic fluxes, it imbues the system with flexibility and fine control. This paradigm shift invites a reevaluation of neurological mechanisms underlying metabolic diseases, encouraging exploration beyond traditional endocrine models.

Future work aims to dissect how these neurons collectively coordinate to manage the body’s glucose economy across varying conditions. By mapping the intricate neural circuits within the ventromedial hypothalamus and their systemic targets, scientists aspire to unveil comprehensive regulatory frameworks governing metabolism. Moreover, understanding the crosstalk between the central nervous system and peripheral organs like the liver and pancreas will deepen knowledge of integrated metabolic control.

This investigation, spearheaded by members of the Caswell Diabetes Institute at the University of Michigan, marks a milestone in neuroscience and metabolism research. It melds sophisticated genetic, physiological, and biochemical approaches to illuminate previously cryptic aspects of neuroendocrinology. The team’s discoveries underscore the brain’s proactive stewardship over glucose balance, challenging preconceived notions and hinting at novel therapeutic strategies for diabetes, one of the world’s most pressing health concerns.

Ongoing inquiries will explore how modulation of VMH^Cckbr neuron activity influences metabolic outcomes in different physiological and pathological states. Additionally, determining how environmental and lifestyle factors intersect with this neuronal circuitry may unveil new preventive measures for metabolic disorders. The fine-grained understanding achieved here sets a precedent for unraveling other brain-controlled metabolic pathways and their role in systemic health.

In conclusion, the University of Michigan study redefines the role of the hypothalamus from merely an emergency responder to a vigilant regulator of glucose homeostasis during everyday life. Through its control over lipolysis and provision of gluconeogenic substrates, the VMH^Cckbr neuronal population ensures a steady glucose supply during fasting, thereby averting hypoglycemia and maintaining metabolic harmony. This nuanced regulation offers fresh perspectives on the neural basis of metabolic diseases and paves the way for innovative interventions tailored to the brain’s complex control of energy balance.

Subject of Research: Animals

Article Title: Control of physiologic glucose homeostasis via hypothalamic modulation of gluconeogenic substrate availability

News Publication Date: 18-Jul-2025

Web References:
https://www.sciencedirect.com/science/article/pii/S2212877825001231
http://dx.doi.org/10.1016/j.molmet.2025.102216

References:
“Control of physiologic glucose homeostasis via hypothalamic modulation of gluconeogenic substrate availability,” Molecular Metabolism, DOI: 10.1016/j.molmet.2025.102216

Image Credits: Angel Ren

Keywords: Health and medicine

The study, published in the peer-reviewed journal Psychedelics, centers on the selective serotonin 2A receptor agonist 25CN-NBOH. This compound, a novel psychedelic, was administered once to experimental mice, and the animals’ cognitive flexibility was assessed using rigorous reversal learning tasks 15 to 20 days post-treatment. Remarkably, the treated mice displayed superior performance during these tasks compared to their control counterparts, highlighting sustained improvements in their ability to adapt and learn new rules after changing conditions.

Central to this research was the use of an automated sequential learning paradigm, which refined the precision and throughput of behavioral testing. This method involved requiring mice to perform a sequence of nose-poke responses within a 30-second window to earn a reward. Initially, mice had to poke left and then right to receive a pellet reward; however, during the reversal phase, the rule switched such that they had to poke right followed by left. The psychedelic-treated mice adapted to these reversals with significantly more efficiency, demonstrating elevated percentages of correct trials and an enhanced rate of reward acquisition.

Professor Omar J. Ahmed, senior author of the study and psychologist at the University of Michigan, highlights the significance of these findings: “Our data showed that the cognitive enhancements induced by a single psychedelic dose were not only substantial but remarkably persistent. The longevity of these effects suggests the psychedelic may instigate durable neuroplastic changes within the prefrontal cortex, a brain region integral to flexible cognitive control and complex decision-making.”

Neuroplasticity—the brain’s ability to remodel its structural and functional networks in response to experience—has long been a target of novel therapeutics for conditions characterized by rigid thinking patterns or diminished adaptability, such as depression, post-traumatic stress disorder, and neurodegenerative diseases. Previous cellular studies have documented that psychedelics can promote dendritic growth and synaptic remodeling, but this study is among the first to connect these molecular changes to lasting functional improvements in behavior.

One compelling question arising from this work pertains to the molecular underpinnings mediating the long-term cognitive benefits observed. Engagement of the serotonin 2A receptor by psychedelic molecules is known to trigger a cascade of intracellular signaling pathways involving brain-derived neurotrophic factor (BDNF), immediate early genes such as c-fos, and modulation of glutamatergic transmission. These mechanisms are believed to facilitate synaptic remodeling and the stabilization of new neural circuits, yet precisely how this translates into durable behavioral enhancements remains a rich area for further inquiry.

Moreover, this study raises provocative considerations about whether psychedelics could potentially reopen critical windows of plasticity in the adult brain. Such “critical period reopening” might enable more effective behavioral reprogramming and therapeutic interventions for psychiatric disorders that have traditionally been challenging to treat. The possibility of a pharmacologically induced “reset” of neural adaptability adds a conceptual dimension rarely seen in the pharmacotherapy of cognitive deficits.

Gender differences in response to psychedelics have often been a subject of scientific debate. The current findings show that improvements in cognitive flexibility were evident in both male and female mice, underscoring the broad utility of these compounds across sexes. This inclusive effect opens the door to more generalized therapeutic strategies, minimizing concerns regarding sex-specific variability in treatment outcomes.

Elizabeth J. Brouns, the study’s first author, emphasizes the transformative potential of these findings for clinical practice: “Our research indicates that a single dose of a psychedelic works not only in the short term by altering perception, but also induces enduring beneficial modifications in brain function. This suggests new avenues for dosing regimens that maximize therapeutic benefits while minimizing exposure and potential side effects.”

Methodologically, the use of an automated and high-throughput behavioral testing apparatus stands out as a substantial advancement for the field. This system permits a more objective, reproducible, and scalable assessment of cognitive flexibility and can be easily adapted to screen future psychedelic compounds or other neuroactive drugs. By reducing human intervention and bias, automated testing bolsters reproducibility and accelerates the pace of discovery.

Looking ahead, the researchers highlight several critical questions that must be addressed to leverage these findings for clinical application. Notably, how do multiple dosing schedules affect neuroplasticity and cognitive outcomes? Does the benefit plateau or potentially wane with repeated administration? Could there be threshold or tolerance effects that constrain long-term efficacy? Systematic investigations into these parameters will be crucial to designing optimized and mechanistically informed psychedelic treatment protocols.

The implications of this work extend beyond neuropsychiatry to the broader landscape of brain science. By illustrating how a single psychedelic dose can promote long-term cognitive enhancements and adaptive flexibility, the findings challenge prior assumptions regarding the temporal window of psychedelic action and encourage deeper exploration into the interaction between pharmacology and enduring neurocognitive remodeling.

Support for this study was provided by the National Institutes of Health and the University of Michigan Eisenberg Family Depression Center. The research team included co-author Dr. Tyler Ekins, alongside Professors Ahmed and Brouns. The full publication is accessible through the journal Psychedelics, which is dedicated to broad multidisciplinary investigations of consciousness-altering substances and their diverse biological, clinical, and societal implications.

As the resurgence of psychedelic science gathers momentum, these findings illuminate the tantalizing possibility that these compounds may possess the capacity to rewrite the rules of brain plasticity, offering hope for innovative treatments that target the core neurobiological substrates of mental health disorders. Continued interdisciplinary research combining behavioral neuroscience, cellular biology, and clinical science promises to unravel the complex neuropharmacology of psychedelics, ultimately translating groundbreaking basic science into tangible therapeutic advances.

Subject of Research: Animals

Article Title: Single-dose psychedelic enhances cognitive flexibility and reversal learning in mice weeks after administration

News Publication Date: 22-Apr-2025

Web References: http://dx.doi.org/10.61373/pp025r.0002

Image Credits: Dr. Omar J. Ahmed

Keywords: psychedelics, cognitive flexibility, 25CN-NBOH, reversal learning, neuroplasticity, serotonin 2A receptor, prefrontal cortex, behavioral neuroscience, psychedelic therapy, neuropsychiatry, automated behavioral testing, sex differences